Articles by Michael B. Glomb

Covered entities in the 340B Discount Drug Program now can verify that drug manufacturers are charging them no more than the “ceiling price” for a given drug. On Monday, April 1, the Office of Pharmacy Affairs (OPA), the agency within the Health Resources and Services Administration (HRSA) that oversees the…

On January 31, 2019, the Trump Administration announced proposed changes to safe harbor protections under the Anti-Kickback Statute (AKS), which could impact the pharmaceutical market and indirectly the 340B Discount Drug Program. The Department of Health and Human Services (HHS) proposed modifications which would exclude pharmaceutical manufacturer rebates (and other…

On December 27, hospitals participating in the federal 340B drug discount program that are paid under the Medicare Outpatient Prospective Payment System (OPPS) scored a major victory in their fight against severe 340B drug reimbursement cuts finalized in November 2017.[i]  The American Hospital Association, America’s Essential Hospitals, the Association of…

On August 1, the Energy & Commerce Committee (E&C Committee) of the House of Representatives sent letters to nine contract pharmacies that participate in the 340B Drug Pricing Program (340B Program), requesting information about their participation in the program. The contract pharmacy recipients included Accredo Health Group, Albertsons Companies, Avella…